MEK inhibitors for the treatment of non-small cell lung cancer

BRAF and KRAS are two key oncogenes in the RAS/RAF/MEK/MAPK signaling pathway. Concomitant mutations in both KRAS and BRAF genes have been identified in non-small cell lung cancer (NSCLC). They lead to the proliferation, differentiation, and apoptosis of tumor cells by activating the RAS/RAF/MEK/ERK...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Jing, Liu, Yang, Yang, Sen, Wu, Xuan, Li, Hongle, Wang, Qiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786519/
https://www.ncbi.nlm.nih.gov/pubmed/33402199
http://dx.doi.org/10.1186/s13045-020-01025-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7786519/
https://www.ncbi.nlm.nih.gov/pubmed/33402199
http://dx.doi.org/10.1186/s13045-020-01025-7

Ejemplares similares